Pharmaceuticals
Innovent Announces the NMPA Granted New Indication Approval for BYVASDA® (Bevacizumab Biosimilar) for the Treatment of Adult Recurrent Glioblastoma
SAN FRANCISCO and SUZHOU, China, Dec. 28, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2020-12-28 08:00
8190
Arctic Vision obtains the first IND approval for the treatment of UME in China, Suprachoroidal space (SCS) injection potentially brings more benefits to patients
SHANGHAI, Dec. 25, 2020 /PRNewswire/ -- Arctic Vision, a China-based clinical-stage ophthalmology company with a leading portfolio of breakthrough technologies, announced on December 24th the clearance of the Investigational New Drug (IND) for Phase III trial of ARVN001 (triamcinolone acetonide s...
2020-12-25 21:00
3351
INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet's EClinicalMedicine
Peer-reviewed Phase 1 data shows INO-4800 to be immunogenic in 100% of subjects, inducing neutralizing antibody and/or T cell responses INO-4800 demonstrates favorable safety and tolerability, with no serious adverse events reported Offers best-in-class thermostability, including a five-year pro...
2020-12-24 23:12
7387
Foresee Pharmaceuticals Announces Completion of US$47 Million Financing
TAIPEI, Dec. 24, 2020 /PRNewswire/ -- Foresee pharmaceuticals (TPEx: 6576.TWO) ("Foresee") announces that it has successfully completed an underwritten public offering of 15,000,000 shares of its common stock to the public at a price of NT$88 per share. The aggregate gross proceeds to Foresee from...
2020-12-24 18:00
10505
Senhwa Biosciences Receives US FDA 'Study May Proceed' Letter to Treat BRCA2+ or PALB2+ Solid Tumors With CX-5461
TAIPEI and SAN DIEGO, Dec. 23. 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that it has received a "Study May Proceed" letter fr...
2020-12-24 10:40
2879
LycovaryTM Daily provides anti-ageing oxygenation of the ovaries to help women with PMS, painful periods and comfortable menopause transition
CAMBRIDGE, England, Dec. 24, 2020 /PRNewswire/ -- Cambridge Diagnostic Imaging,
CaDi, (cadifamily.com
2020-12-24 08:00
3796
Conbercept: New Generation of Product for Treatment of nAMD Completes 36-week Primary Endpoint Visits of Phase III Trial
CHENGDU, China, Dec. 23, 2020 /PRNewswire/ -- Chengdu Kanghong Pharmaceutical Group ("Kanghong") announced a key development milestone of its key product conbercept last month. Kanghong is seeking global approval of conbercept by undertaking a multicenter, multinational, double-masked, parallel-gr...
2020-12-23 22:40
6301
I-Mab Announces Upcoming Participation at January Conferences
SHANGHAI and GAITHERSBURG, Md., Dec. 23, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in Januar...
2020-12-23 21:00
5753
Innovent Announces NMPA Granted New Indication Approvals for SULINNO® (Adalimumab Injection) for the Treatment of Pediatric Plaque Psoriasis and Non-infectious Uveitis
SAN FRANCISCO and SUZHOU, China, Dec. 23, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2020-12-23 12:30
8820
Hyundai Bioscience Develops Injection Drug for Potential Treatment of Severe Cases of COVID-19
SEOUL, South Korea, Dec. 22, 2020 /PRNewswire/ -- Hyundai Bioscience (KOSDAQ symbol: 048410) announced on the 23rd, December 2020, that CNPharm, its major shareholding bio tech company, has succeeded in developing 'Poly-COV01,' an injection drug for thepotential treatment of patients with severe ...
2020-12-23 10:09
1682
RedHill's Phase 2/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous Recommendation to Continue
Independent DSMB unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib in severe COVID-19 based on review of unblinded safety data from 155 treated patients Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021 Top-line d...
2020-12-22 20:38
4540
Overweight and Obese Subjects Dosed with ASC41 Tablets in a Phase Ib Trial
SHANGHAI, Dec. 22, 2020 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) and fully dedicated to the R&D and commercialization of new drugs in the field of NASH, announces today dosing of overweight and obese subjects in a Phase Ib trial of ASC41, an oral tablet,...
2020-12-22 19:18
3049
Pierre Fabre Selects AGC Biologics as CDMO to manufacture the orphan drug ER-004
SEATTLE, Dec. 21, 2020 /PRNewswire/ -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced its partnership with Laboratoire Pierre Fabre to manufacture ER-004 – an intra-amniotic drug that will pioneer the treatment of a rare and...
2020-12-21 23:00
1602
Pierre Fabre Selects AGC Biologics as CDMO to manufacture the orphan drug ER-004
SEATTLE, Dec. 21, 2020 /PRNewswire/ -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced its partnership with Laboratoire Pierre Fabre to manufacture ER-004 – an intra-amniotic drug that will pioneer the treatment of a rare and...
2020-12-21 23:00
2874
LT1001 (Naldebain(R)), an Extended-Release Analgesic Injection, Received Its Second Approval from Singapore's HSA
TAIPEI, Dec. 21, 2020 /PRNewswire/ -- Lumosa Therapeutics is pleased to announce the market approval of LT1001 (Naldebain®), an extended-release analgesic injection, fromSingapore's Health Science Agency (HSA). HSA is regarded as one of the regulatory reference countries in the world. The approv...
2020-12-21 22:08
1995
Longevity Acquisition Corporation Announces 4D pharma Joining Landmark Parkinson's Progression Markers Initiative
NEW YORK, Dec. 21, 2020 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that onDecember 18, 2020, 4D pharma plc (AIM: DDDD) ("4D pharma"), a pharmaceutical company leading the development of L...
2020-12-21 21:00
10879
BioVaxys Vaccine Platform Stimulates Robust T-cell Response Against Viral Antigens
VANCOUVER, British Columbia, Dec. 21, 2020 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:LMNGF) ("BioVaxys") announced today that further analysis of the data from a preclinical animal study (also known as the "murine model study") of its haptenized viral protein vaccine tech...
2020-12-21 21:00
2410
ImmuneMed's hzVSF-v13, COVID-19 clinical trials accelerate development of the treatment
Followed by Russia, Indonesia, and Korea, the second phase of the COVID-19 clinical trial was approved inItaly on Friday, December 18, 2020. CHUNCHEON, South Korea, Dec. 20, 2020 /PRNewswire/ -- The broad spectrum antiviral therapeutic, 'hzVSF-v13(humanized Virus Suppressing Factor)' being devel...
2020-12-21 10:43
1173
Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
SHANGHAI and HONG KONG, Dec. 21, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) submitted by its partner Karyopharm Therapeutics Inc. (Nasdaq...
2020-12-21 08:00
3947
Teijin Pharma and TransThera Biosciences Form Strategic R&D Collaboration
TOKYO and NANJING, China, Dec. 18, 2020 /PRNewswire/ -- Teijin Pharma Limited
2020-12-18 23:30
3469
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7722
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7116